Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy
- 31 January 2006
- journal article
- research article
- Published by Elsevier BV in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 98 (1), 36-40
- https://doi.org/10.1016/j.jsbmb.2005.07.002
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathwayOncogene, 2003
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003
- HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast CancerJournal of Clinical Oncology, 2003
- Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast CancerJNCI Journal of the National Cancer Institute, 2003
- c-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER +) breast cancer patients with poor prognosisAnnals Of Oncology, 2001
- Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatmentThe Breast, 2001
- Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapyBritish Journal of Cancer, 1995
- ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancerCancer Letters, 1994
- Correlation of HER-2/neu Amplification With Expression and With Other Prognostic Factors in 1103 Breast CancersJNCI Journal of the National Cancer Institute, 1992
- Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancerBritish Journal of Cancer, 1992